Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity
- 11 March 2015
- Vol. 350 (mar11 4), h1059
- https://doi.org/10.1136/bmj.h1059
Abstract
A cascade of failure Polypharmacy, defined as the chronic co-prescription of several drugs, is often the consequence of the application of disease specific guidelines, targeting disease specific goals, to patients with multiple chronic diseases. One common consequence of polypharmacy is the high rate of adverse drug reactions, mainly from drug-drug interactions (the ability of a drug to modify the action or effect of another drug administered successively or simultaneously).1 The risk of a drug-drug interaction in any particular patient increases with the number of co-existing diseases and the number of drugs prescribed.2 In a linked paper, Dumbreck and colleagues (doi:10.1136/bmj.h949) selected three clinical guidelines produced by the National Institute for Health and Care Excellence (NICE)—type 2 diabetes, heart failure, and depression—and systematically looked for possible drug-disease and drug-drug interactions in relation to another 11 NICE guidelines for potentially comorbid chronic conditions.3 Drug-disease interactions were relatively uncommon and mostly occurred between the recommended drug and chronic kidney disease. But the authors identified many potentially serious drug-drug interactions, most of which were overlooked by the index guideline. In general, few disease specific guidelines consider that target patients can also have other diseases, treated …This publication has 12 references indexed in Scilit:
- Understanding adverse drug reactions in older adults through drug–drug interactionsEuropean Journal of Internal Medicine, 2014
- Strategies to reduce the risk of iatrogenic illness in complex older adultsAge and Ageing, 2013
- How to Integrate Multiple Comorbidities in Guideline DevelopmentProceedings of the American Thoracic Society, 2012
- Drug Policy for an Aging Population — The European Medicines Agency's Geriatric Medicines StrategyThe New England Journal of Medicine, 2012
- Systems biology and the future of medicineWires Systems Biology and Medicine, 2011
- Potentially severe drug interactions in elderly outpatients: results of an observational study of an administrative prescription databaseJournal of Clinical Pharmacy & Therapeutics, 2009
- A population-based study of the drug interaction between proton pump inhibitors and clopidogrelCMAJ : Canadian Medical Association Journal, 2009
- A vision statement on guideline development for respiratory disease: the example of COPDThe Lancet, 2009
- Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)European Heart Journal, 2006
- Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)European Heart Journal, 2005